Tealwood Asset Management Inc. Buys 3,920 Shares of Lantheus Holdings, Inc. $LNTH

Tealwood Asset Management Inc. lifted its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 36.6% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 14,639 shares of the medical equipment provider’s stock after purchasing an additional 3,920 shares during the quarter. Tealwood Asset Management Inc.’s holdings in Lantheus were worth $1,198,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in LNTH. Signaturefd LLC boosted its position in Lantheus by 36.5% during the 1st quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider’s stock worth $42,000 after buying an additional 116 shares during the period. Quarry LP boosted its position in Lantheus by 2,350.0% during the 1st quarter. Quarry LP now owns 490 shares of the medical equipment provider’s stock worth $48,000 after buying an additional 470 shares during the period. Hughes Financial Services LLC acquired a new stake in Lantheus during the 1st quarter worth approximately $81,000. UMB Bank n.a. boosted its position in Lantheus by 68.2% during the 1st quarter. UMB Bank n.a. now owns 940 shares of the medical equipment provider’s stock worth $92,000 after buying an additional 381 shares during the period. Finally, Blue Trust Inc. boosted its position in Lantheus by 117.7% during the 1st quarter. Blue Trust Inc. now owns 1,171 shares of the medical equipment provider’s stock worth $114,000 after buying an additional 633 shares during the period. 99.06% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on LNTH shares. William Blair reiterated a “market perform” rating on shares of Lantheus in a research report on Wednesday, July 16th. Mizuho cut their target price on shares of Lantheus from $120.00 to $70.00 and set an “outperform” rating on the stock in a research report on Thursday, August 7th. TD Cowen cut their target price on shares of Lantheus from $95.00 to $80.00 and set a “buy” rating on the stock in a research report on Monday, September 15th. Truist Financial set a $63.00 price target on shares of Lantheus and gave the stock a “hold” rating in a report on Monday, August 11th. Finally, JMP Securities lowered their price target on shares of Lantheus from $112.00 to $73.00 and set a “market outperform” rating for the company in a report on Thursday, August 7th. Five analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Lantheus currently has an average rating of “Moderate Buy” and an average target price of $85.50.

Lantheus Stock Up 0.0%

Lantheus stock opened at $50.62 on Tuesday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 4.07 and a current ratio of 4.29. Lantheus Holdings, Inc. has a 52-week low of $47.25 and a 52-week high of $118.21. The firm has a 50 day moving average price of $57.99 and a two-hundred day moving average price of $77.39. The firm has a market cap of $3.44 billion, a price-to-earnings ratio of 13.46 and a beta of 0.15.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Wednesday, August 6th. The medical equipment provider reported $1.57 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.08). The company had revenue of $378.05 million during the quarter, compared to the consensus estimate of $389.69 million. Lantheus had a net margin of 17.82% and a return on equity of 34.06%. The business’s revenue was down 4.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.80 EPS. Equities analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Insider Buying and Selling at Lantheus

In other news, insider Farallon Partners L. L C/Ca sold 3,365,000 shares of Lantheus stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total value of $188,944,750.00. Following the completion of the sale, the insider owned 3,477,227 shares in the company, valued at $195,246,296.05. The trade was a 49.18% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Rajiv A. Patel sold 3,365,000 shares of Lantheus stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the completion of the sale, the insider owned 3,477,227 shares of the company’s stock, valued at $195,246,296.05. This represents a 49.18% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 6,812,000 shares of company stock valued at $382,427,380 in the last quarter. 2.00% of the stock is currently owned by company insiders.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.